Cost-Benefit Case for Expensive Up-Front Treatments

Eli Lilly has raised its full-year forecast after unprecedented international demand for its hit weight-loss and diabetes drugs, Mounjaro and Zepbound. The pharmaceutical giant’s booming sales and rapid global expansion signal a new era for obesity treatment worldwide.

• Get the top 40+ AI Models for $20 at AI Box: ⁠⁠https://aibox.ai

• AI Chat YouTube Channel: https://www.youtube.com/@JaedenSchafer

• Join my AI Hustle Community: https://www.skool.com/aihustle

See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.